Q32 Bio Inc. (NasdaqCM: QTTB)
Health Care · Biotechnology · US
$16.32
+7.72% today · +642.6% 1Y
Q32 Bio Inc. (NasdaqCM: QTTB) operates in the Biotechnology industry within the Health Care sector. The company is valued at $451.01M and employs 22 people.
Over the last twelve months the share price has gained 642.6%, trading between 1.62 and 23.57.
Tweenvest scores Q32 Bio Inc. across four factors: quality 57/100, value 24/100. Its strongest factor is quality.
QTTB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $451.01M
- Revenue (TTM)
- $53.74M
- P/E
- 6.67
- EPS
- 2.27
- Dividend yield
- —
- Beta (5Y)
- -0.33
- 52-week high
- $23.57
- 52-week low
- $1.62
- Avg volume (3M)
- —
- Shares outstanding
- 29.77M
- Employees
- 22
- Next earnings
- —
About Q32 Bio Inc.
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
- ISIN
- US7469641051
- Founded
- 2017
- Listed since
- Mar 28, 2018
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.